This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. On Thursday, July 6, 2023, U.S. officials granted full approval to the closely watched Alzheimer’s drug, clearing the way for Medicare and other insurance plans to begin covering the treatment for people with the brain-robbing disease. (Eisai via AP, File)
By Matthew Perrone
U.S. officials granted full approval to a closely watched Alzheimer’s drug on Thursday, clearing the way for Medicare and other insurance plans to begin covering the treatment for people with the brain-robbing disease.
The Food and Drug Administration endorsed the IV drug, Leqembi, for patients with mild dementia and other symptoms caused by early Alzheimer's disease. It’s the first medicine that’s been convincingly shown to modestly slow Alzheimer’s cognitive decline.
Japanese drugmaker Eisai received conditional approval from the FDA in January based on early results suggesting Leqembi worked by clearing a sticky brain plaque linked to the disease.
The FDA confirmed those results by reviewing data from a larger, 1,800-patient study in which the drug slowed memory and thinking decline by about five months in those who got the treatment, compared to those who got a dummy drug.
“This confirmatory study verified that it is a safe and effective treatment for patients with Alzheimer’s disease," said FDA's neurology drug director, Teresa Buracchio, in a statement.
The drug's prescribing information will carry the most serious type of warning, indicating that Leqembi can cause brain swelling and bleeding, side effects that can be dangerous in rare cases. The label notes that those problems are seen with other plaque-targeting Alzheimer's drugs.
The process of converting a drug to full FDA approval usually attracts little attention. But Alzheimer’s patients and advocates have been lobbying the federal government for months after Medicare officials announced last year they wouldn’t pay for routine use of Leqembi until it received FDA’s full approval.
There were concerns that the cost of new plaque-targeting Alzheimer's drugs like Leqembi could overwhelm the program's finances, which provide care for 60 million seniors. Leqembi is priced at about $26,500 for a year’s supply of IVs every two weeks.
The vast majority of Americans with Alzheimer’s get their health coverage through Medicare. And private insurers have followed its lead by withholding coverage for Leqembi and a similar drug, Aduhelm, until they receive FDA's full endorsement. An FDA decision on full approval for Aduhelm is still years away.
Medicare administrator, Chiquita Brooks-LaSure, has made clear the program will immediately begin paying for the drug now that it has full FDA approval. But the government is also setting extra requirements.
Medicare recipients getting Leqembi must be enrolled in a federal registry to track the drug's real-world safety and effectiveness. The information will help advance “knowledge of how these drugs can potentially help people,” Medicare officials said.
Hospitals and medical clinics have also cautioned that it may take time to get people started on the drug.
Doctors need to confirm that patients have the brain plaque targeted by Leqembi before prescribing it. Nurses need to be trained to administer the drug and patients must be monitored with repeated brain scans to check for swelling or bleeding. The imaging and administration services carry extra costs for hospitals beyond the drug itself.
Eisai has told investors that about 100,000 Americans could be diagnosed and eligible to receive Leqembi by 2026. The drug is co-marketed with Cambridge, Massachusetts-based Biogen.
“We want to ensure that appropriate patients only are the ones that get this product,” said Alexander Scott, a vice president with Eisai.
Eisai studied the drug in people with early or mild disease who were evaluated using a scale measuring memory, thinking and other basic skills. After 18 months, those who got Leqembi declined more slowly — a difference of less than half a point on the scale — than participants who received a dummy infusion. Some Alzheimer's experts say that delay is likely too subtle for patients or their families to notice.
But federal health advisers said the difference could still be meaningful and recommended that FDA fully approve the drug at a public meeting in June.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
On this episode of Cheddar Innovates: Founder of Unlimited Tomorrow breaks down how he is creating completely 3D printed prosthetics to make them more affordable, customizable, and accessible; Chief Technology Officer of Zebra Technologies explains what the future of collaboration between robots and humans may look like; A look at Curiosity Stream's 'Mystery of the Roman Skulls.'
Each year about 5,000 people are diagnosed with ALS. This is such an important conversation. A disease that can weaken a patient's muscles and impact physical function. However, one research company says that could all change soon. Coya Therapeutics has developed a way to isolate a patient problematic T-cells in order to help ultimately slow the decline of not just ALS, but potentially Alzheimer's and other neurodegenerative diseases as well. Founder and Chief Executive Officer at Coya Therapeutics, Dr. Howard Berman, joined Cheddar to discuss more.
In the fight against climate change, much of the conversation revolves around reducing greenhouse gases like carbon dioxide or methane - and attempting to raise oxygen levels. But there's another gas - hydrogen - that could play a big role in the fight for the climate. Marco Alvera, CEO of Italian energy infrastructure company Snam and author of the book, 'The Hydrogen Revolution,' joined Cheddar Climate to explain the role hydrogen plays in helping achieve a net-zero future.
Americans looking to purchase at-home COVID-19 tests will now have to shell out a bit more money after an agreement expired between the White House and companies to sell the tests at cost. The price of Abbot's BinaxNow test kit from October to December was $14 apiece; on Tuesday, Walmart's website listed the test for $19.88, and Kroger listed the tests for $23.99. Carbon Health Regional Clinical Director Dr. Bayo Curry-Winchell joined Cheddar News' Closing Bell to discuss the impact higher prices will have as the nation experiences another surge in cases.
As millions of kids go back to school, districts across the country are determined to keep class in person, despite a surge in COVID cases. In New York City, Mayor Eric Adams has vowed to keep the nation's largest school system open amid Omicron, citing the disastrous effect of remote learning on students. Oswald Feliz, NYC council member who sits on the health and education committee, joined Cheddar to discuss the city's plan to combat the recent surge and keep kids in school.
Schools across the country are determined to keep class in session, despite the rapidly-spreading Omicron variant. While many parents prefer in-person learning, they also worry whether the current public health guidelines will be enough to protect their kids. Erin Richards, national education reporter for USA Today, joined Cheddar to discuss how are schools are preparing for the surge to avoid another round of remote learning.
With the annual CES convention underway amid COVID, HP unveiled rolled out a number of new products virtually this year, including new gaming PCs and 4K display monitors. But as industries look toward a greener future, HP is working with the climate crisis in mind. James McCall, chief sustainability officer at HP, joined Cheddar's Kristen Scholer to discuss the company's climate goals, which includes reducing its carbon footprint to net-zero by 2040. He admitted that reaching the ambitious goal will be difficult because much of the company's emissions totals come from third parties. "A large part of our footprint is outside of HP's direct control. A lot of it comes either from our incoming supply chain, the materials, our manufacturing process, or about 30 to 40 percent of it comes from our consumer-use base," McCall told Cheddar.
Pfizer and BioNTech are working to develop an mRNA-based shingles vaccine following the success of the COVID-19 shot. This latest collaboration will mark the third time the pharmaceutical companies have worked together on a vaccine.
The potential collapse of the Thwaites glacier in Antarctica has been deemed a potential "doomsday event" — researchers and scientists say its melting and collapse could raise global sea levels by at least two feet, enough to destroy coastal communities around the world. One team of scientists is traveling to the Thwaites glacier to drill below in order to gauge current ocean temperatures and attempt to model possible outcomes. David Holland, professor at NYU and Principal Investigator for the International Thwaites Glacier Collaboration, joins Cheddar Climate to discuss the glacier's potential collapse, his team's research plan, and more.
As winter break wraps up and COVID-19 cases hit record levels, the majority of school districts are returning to in-person classes. While some public schools in large cities have shifted to remote learning for the beginning of the year, the schools that are reopening campuses are determined to avoid the academic, social, and logistical challenges that come with a virtual classroom. Cheddar News is joined by Keith Powers, NYC Council Member, to discuss.
